Quarterly report pursuant to Section 13 or 15(d)

NON CONTROLLING INTEREST (Details)

v3.24.3
NON CONTROLLING INTEREST (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Net loss attributable to the non-controlling interest     $ (42,960) $ (3,108)
BioCorRx Pharmaceuticals, Inc [Member]        
Net loss $ (106,233) $ (2,397) $ (175,033) $ (5,692)
Average Non-controlling interest percentage of profit/losses 24.20% 24.20% 24.20% 24.20%
Net loss attributable to the non-controlling interest $ (25,708) $ (580) $ (42,358) $ (1,378)
Joseph DeSanto MD [Member]        
Net loss $ 244 $ (1,395) $ (1,720) $ (4,945)
Average Non-controlling interest percentage of profit/losses 35.00% 35.00% 35.00% 35.00%
Net loss attributable to the non-controlling interest $ 85 $ (488) $ (602) $ (1,730)